Effect of pharmacogenetic markers of Vitamin D pathway on deferasirox pharmacokinetics in children

Pharmacogenetics and Genomics

Volumn 28, Issue 1, 2018, Pages 17-22

  Allegra, Sarah ^a   Cusato, Jessica ^a   Francia, Silvia De ^b   Longo, Filomena ^c   Pirro, Elisa ^b   Massano, Davide ^c   Piga, Antonio ^c   D'Avolio, Antonio ^a  

^a AMEDEO DI SAVOIA HOSPITAL   (Italy)

^b Department of Biological and Clinical Sciences ^*  (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

CYP24A1; deferasirox; GC; iron overload; personalized medicine; pharmacogenetics; VDR; Vitamin D; thalassemia

Indexed keywords

APAI PROTEIN; BSML PROTEIN; COLECALCIFEROL 24 HYDROXYLASE; CREATININE; CYP27B1 PROTEIN; DEFERASIROX; FOKL PROTEIN; PROTEIN; TAQL PROTEIN; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR; BENZOIC ACID DERIVATIVE; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL RECEPTOR; CYP24A1 PROTEIN, HUMAN; CYP27B1 PROTEIN, HUMAN; TRIAZOLE DERIVATIVE; VDR PROTEIN, HUMAN;

ADOLESCENT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PHARMACOGENETICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; VOLUME OF DISTRIBUTION; GENETICS; METABOLISM; PHARMACOGENETIC VARIANT; PRESCHOOL CHILD; REGRESSION ANALYSIS;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ADOLESCENT; BENZOATES; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; PHARMACOGENOMIC VARIANTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CALCITRIOL; REGRESSION ANALYSIS; TRIAZOLES; VITAMIN D; VITAMIN D3 24-HYDROXYLASE;

EID: 85038636584     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000315     Document Type: Article

References (37)

1. Ginzburg Y, Rivella S.-Thalassemia: A model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood 2011; 118:4321-4330.
2. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001; 1:47-61.
3. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102:17-24.
4. Cappellini MD. Exjade (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag 2007; 3:291-299.
5. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, pharmacokinetics of ICL670, a new orally active ironchelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43:565-572.
6. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, doseescalation trial. Lancet 2003; 361:1597-1602.
7. De Francia S, Massano D, Piccione FM, Pirro E, Racca S, Di Carlo F, et al. A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 893-894:127-133.
8. Waldmeier F, Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S, et al. Pharmacokinetics, metabolism, disposition of deferasirox in betathalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab Dispos 2010; 38:808-816.
9. Bruin GJ, Faller T, Wiegand H, Schweitzer A, Nick H, Schneider J, et al. Pharmacokinetics, distribution, metabolism, excretion of deferasirox and its iron complex in rats. Drug Metab Dispos 2008; 36:2523-2538.
10. Galanello R, Origa R. Once-daily oral deferasirox for the treatment of transfusional iron overload. Expert Rev Clin Pharmacol 2008; 1:231-240.
11. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orallyadministered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91:873-880.
12. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, et al. Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010; 95:557-566.
13. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study. Eur J Haematol 2008; 80:168-176.
14. Dimitriadou M, Christoforidis A, Fidani L, Economou M, Vlachaki E, Athanassiou-Metaxa M, et al. A 2-year prospective densitometric study on the influence of Fok-I gene polymorphism in young patients with thalassaemia major. Osteoporos Int 2016; 27:781-788.
15. Moulas A, Challa A, Chaliasos N, Lapatsanis PD. Vitamin D metabolites (25-hydroxyvitamin D, 24, 25-dihydroxyvitamin D and 1, 25-dihydroxyvitamin D) and osteocalcin in beta-thalassaemia. Acta Paediatr 1997; 86:594-599.
16. Napoli N, Carmina E, Bucchieri S, Sferrazza C, Rini GB, Di Fede G. Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone 2006; 38:888-892.
17. Wood JC, Claster S, Carson S, Menteer JD, Hofstra T, Khanna R, et al. Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major. Br J Haematol 2008; 141:891-894.
18. Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: Metabolism. Rheum Dis Clin North Am 2012; 38:1-11. vii.
19. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, et al. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, immune system regulation. Mol Endocrinol 2002; 16:1243-1256.
20. Wood RJ, Tchack L, Angelo G, Pratt RE, Sonna LA. DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics 2004; 17:122-129.
21. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, et al. Large-scale in silico and microarray-based identification of direct 1, 25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005; 19:2685-2695.
22. Brittenham GM, Badman DG. Noninvasive measurement of iron: Report of an NIDDK workshop. Blood 2003; 101:15-19.
23. Jensen PD. Evaluation of iron overload. Br J Haematol 2004; 124:697-711.
24. Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ, et al. Linkage disequilibrium in the human genome. Nature 2001; 411:199-204.
25. Cusato J, Allegra S, Massano D, De Francia S, Piga A, D'Avolio A. Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J 2014; 15:263-271.
26. Allegra S, Cusato J, De Francia S, Massano D, Piga A, D'Avolio A. Deferasirox AUC efficacy cutoff and role of pharmacogenetics. Eur J Clin Pharmacol 2016; 72:1155-1157.
27. Cusato J, Allegra S, De Francia S, Massano D, Piga A, D'Avolio A. Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics 2016; 17:561-572.
28. Cusato J, Allegra S, De Nicolo A, Boglione L, Fatiguso G, Mohamed Abdi A, et al. Intracellular and plasma trough concentration and pharmacogenetics of telaprevir. J Pharm Pharm Sci 2015; 18:171-176.
29. Fatiguso G, Allegra S, Calcagno A, Baietto L, Motta I, Favata F, et al. Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. Int J Pharm 2015; 497:287-292.
30. Cusato J, Allegra S, Boglione L, De Nicolo A, Baietto L, Cariti G, et al. Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. Antivir Ther 2014; 20:335-341.
31. Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 2000; 14:401-420.
32. Andraos C, Koorsen G, Knight JC, Bornman L. Vitamin D receptor gene methylation is associated with ethnicity, tuberculosis, TaqI polymorphism. Hum Immunol 2011; 72:262-268.
33. Anderson LN, Cotterchio M, Cole DE, Knight JA. Vitamin D-related genetic variants, interactions with vitamin D exposure, breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev 2011; 20:1708-1717.
34. Cancado R, Melo MR, de Moraes Bastos R, Santos PC, Guerra-Shinohara EM, Ballas SK, et al. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: Results of a 1-year Phase 2 study. Eur J Haematol 2015; 95:545-550.
35. Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 2010; 34:864-870.
36. Neukirchen J, Fox F, Kundgen A, Nachtkamp K, Strupp C, Haas R, et al. Improved survival in MDS patients receiving iron chelation therapy-a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res 2012; 36:1067-1070.
37. Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. Leuk Res 2012; 36:1380-1386.